Effectiveness of the Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): A Randomized, Controlled, Double-Blind Study

被引:58
|
作者
Spaniel, Filip [1 ]
Hrdlicka, Jan [2 ]
Novak, Tomas [1 ]
Kozeny, Jiri [1 ]
Hoeschl, Cyril [1 ]
Mohr, Pavel [1 ]
Motlova, Lucie Bankovska [1 ]
机构
[1] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Ctr Neuropsychiat Studies, Prague 18103 8, Czech Republic
[2] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic
关键词
schizophrenia; psychotic disorders; relapse prevention; hospitalizations; antipsychotic medication; information technology; FOLLOW-UP; THERAPY; PREDICTION; SYMPTOMS; EPISODE; COSTS; SIGNS;
D O I
10.1097/01.pra.0000416017.45591.c1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose. To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). Methods. Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n = 75) or control group (n = 71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological intervention requiring event (PIRE) detected by ITAREPS. Results. Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR] = 10.8; 95% confidence interval [CI] 1.4-80.0; p = 0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n = 25) compared with the ITAREPS Non-interventional group (INIs, n = 70; Kaplan-Meier survival analysis, HR = 0.11, 95% CI 0.05-0.28, p = 0.009; number needed to treat [NNT] = 4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p < 0.05) and costs (p < 0.05). Conclusion. Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. Trial registration: Clinical Trials NCT00712660 (Journal of Psychiatric Practice 2012; 18: 269-280)
引用
收藏
页码:269 / 280
页数:12
相关论文
共 50 条
  • [1] Information technology aided relapse prevention in schizophrenia: ITAREPS
    Spaniel, F.
    Motlova, L.
    EUROPEAN PSYCHIATRY, 2007, 22 : S140 - S140
  • [2] ITAREPS:: Information technology aided relapse prevention programme in schizophrenia
    Spaniel, Filip
    Vohlidka, Pavel
    Hrdlicka, Jan
    Kozeny, Jiri
    Novak, Tomas
    Motlova, Lucie
    Cermak, Jan
    Bednarik, Josef
    Novak, Daniel
    Hoschl, Cyril
    SCHIZOPHRENIA RESEARCH, 2008, 98 (1-3) : 312 - 317
  • [3] Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: A randomized controlled trial
    Komatsu, Hideki
    Sekine, Yoshimoto
    Okamura, Naoe
    Kanahara, Nobuhisa
    Okita, Kyoji
    Matsubara, Saburo
    Hirata, Toyoaki
    Komiyama, Tokutaro
    Watanabe, Hiroyuki
    Minabe, Yoshio
    Iyo, Masaomi
    SCHIZOPHRENIA RESEARCH, 2013, 150 (01) : 240 - 244
  • [4] ITAREPS: Information technology aided relapse prevention programme in schizophrenia. A two-year mirror design follow up evaluation
    Spaniel, F.
    Hrdlicka, J.
    Novak, T.
    Motlova, L.
    Hoschl, C.
    EUROPEAN PSYCHIATRY, 2008, 23 : S148 - S148
  • [5] A program for relapse prevention in schizophrenia -: A controlled study
    Herz, MI
    Lamberti, JS
    Mintz, J
    Scott, R
    O'Dell, SP
    McCartan, L
    Nix, G
    ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (03) : 277 - 283
  • [6] A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
    Beasley, CM
    Sutton, VK
    Hamilton, SH
    Walker, DJ
    Dossenbach, M
    Taylor, CC
    Alaka, KJ
    Bykowski, D
    Tollefson, GD
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (06) : 582 - 594
  • [7] CHARACTERISTICS ASSOCIATED WITH RELAPSE IN PATIENTS WITH SCHIZOPHRENIA: POST HOC ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CARIPRAZINE RELAPSE PREVENTION TRIAL
    Kunovac, Jelena
    Kane, John
    Durgam, Suresh
    Chang, Cheng-Tao
    Nemeth, Gyorgy
    Laszlovszky, Istvan
    Earley, Willie
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S165 - S166
  • [8] Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
    Durgam, Suresh
    Earley, Willie
    Li, Rui
    Li, Dayong
    Lu, Kaifeng
    Laszlovszky, Istvan
    Fleischhacker, W. Wolfgang
    Nasrallah, Henry A.
    SCHIZOPHRENIA RESEARCH, 2016, 176 (2-3) : 264 - 271
  • [9] Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia : A 12-month, double-blind study
    Loebel, A.
    Cucchiaro, J.
    Xu, J.
    Sarma, K.
    Pikalov, A.
    Kane, J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 125 - 125
  • [10] EFFECTIVENESS OF LURASIDONE VS. QUETIAPINE XR FOR RELAPSE PREVENTION IN SCHIZOPHRENIA: A 12-MONTH, DOUBLE-BLIND STUDY
    Loebel, Antony
    Cucchiaro, Josephine
    Xu, Jane
    Sarma, Kaushik
    Pikalov, Andrei
    Kane, John M.
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S260 - S260